U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Bayer AG

17/04/2026 23:47

NEW YORK, April 17 (Reuters) - A federal judge rejected Bayer's BAYGn.DE request for an injunction to block Johnson & Johnson's JNJ.N alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer in half.

In a Friday night decision, U.S. District Judge Dale Ho in Manhattan said Bayer was unlikely to succeed on the merits of its claims, which included that Johnson & Johnson's campaign for its drug Erleada caused irreparable harm and threatened to erode trust in Bayer's own drug Nubeqa.

 (Reporting by Jonathan Stempel in New York
Editing by Nick Zieminski)

 ((jon.stempel@thomsonreuters.com ; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net /))